Placebo to match Tebipenem pivoxil clinical trials

A Phase 3, randomized, double-blind, double-dummy, multicenter, multinational study to assess the efficacy and safety of orally administered tebipenem pivoxil hydrobromide (TBP-PI-HBr) compared to intravenously (IV) administered imipenem-cilastatin in patients with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP)

This study is looking at a new tablet treatment for serious urinary tract infections (UTIs) and kidney infections. It compares this new tablet with a standard IV (into the vein) treatment to see if it's safe and works well.